LEK S.a. Pharmaceutical Import Profile — Poland (DGFT 2022–2026)

Name: LEK S.a. Pharmaceutical Import Records from India — 2 Products, $11.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

LEK S.a. — Pharmaceutical Importer Profile (2026) | 2 Products, $11.3M Trade | TransData Nexus

LEK S.a.

Pharmaceutical Importer · Poland · CNS & Psychiatric Focus · $11.3M Total Trade · DGFT Verified

LEK S.a. is a pharmaceutical importer based in Poland with a total trade value of $11.3M across 2 products in 1 therapeutic categories. Based on 286 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. LEK S.a. sources from 1 verified Indian supplier, with Sandoz Private Limited accounting for 100.0% of imports.

LEK S.a. — Import Portfolio & Supplier Network

LEK S.a. import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to LEK S.a.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sandoz Private Limited	$2.1M	55	100.0%

LEK S.a. sources from 1 verified Indian supplier across 25 distinct formulations. The sourcing is highly concentrated — Sandoz Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does LEK S.a. Import?

Formulation	Value	Ships
Escitalopram oxa fct 10MG in91 sh eu	$350.0K	7
Material no. - 42031996 naratriptan hclfct 2.5MG in91c sh	$309.7K	10
Material no. - 42034110 escitalopram	$300.0K	6
Escitalopram oxa fct 10MG in91 sh eu 06material no	$200.0K	4
Escitalopram oxa fct 20MG in91 sh eu 07material no	$150.0K	3
Material no 42034100 escitalopram oxafct 20MG in91 sh eu	$98.7K	2
Material no. - 42031967 donepezil hcl	$69.7K	3
Material no. - 42031966 donepezil hcl fct 5MG in91c sh	$52.9K	3
Material no 42032060 escitalopram oxafct 20MG in91c sh	$50.0K	1
Material no 42034110 escitalopram oxafct 10MG in91 sh eu	$50.0K	1
Material no 42031966 donepezil hcl fct 5MG in91c sh	$50.0K	1
Material no 42034091 escitalopram oxafct 15MG in91 sh eu	$50.0K	1
Material no. - 42034100 escitalopram	$50.0K	1
Escitalopram oxa fct 20MG in91 sh eu	$50.0K	1
Material no. - 42034091 escitalopram	$50.0K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Citalopram	CNS & Psychiatric	$5.6M	143	1.6%	7
2	Escitalopram	CNS & Psychiatric	$5.6M	143	2.1%	4

LEK S.a. imports 2 pharmaceutical products across 1 categories into Poland totaling $11.3M.

LEK S.a. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

LEK S.A. is a pharmaceutical company headquartered in Stryków, Poland, operating as a subsidiary of Sandoz, a global leader in generic drugs. Since January 2010, the company has been known as Sandoz in Poland, continuing the legacy of the Lek Polska and Hexal brands. LEK S.A. is recognized as one of the leaders in the Polish generic drug market.

The company specializes in the manufacturing of pharmaceutical preparations, focusing on the production of generic medicines and biosimilars. Its facility in Stryków is known for high-quality drug production and innovative solutions.

2Distribution Network

LEK S.A. operates a centralized distribution network from its Stryków facility, ensuring efficient logistics and supply chain management within Poland. While specific warehouse locations and logistics capabilities are not publicly detailed, the company's integration within the Sandoz group suggests access to a robust distribution infrastructure. This network facilitates the delivery of pharmaceutical products across Poland and potentially to other European markets.

3Industry Role

In Poland's pharmaceutical supply chain, LEK S.A. functions primarily as a pharmaceutical manufacturer, producing generic medicines and biosimilars. The company does not operate as a wholesaler, parallel importer, hospital supplier, or logistics intermediary. Its role is centered on the development, manufacturing, and marketing of generic pharmaceutical products.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — LEK S.a.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

LEK S.A. imports finished pharmaceutical formulations exclusively from Sandoz Private Limited, with a total import value of $11.3 million USD over 286 shipments. This indicates a high supplier concentration, with Sandoz accounting for 100% of LEK S.A.'s imports from India. Such single-source dependency can pose risks, including supply chain disruptions and limited negotiation leverage. However, the consistent volume of shipments suggests a stable and long-term relationship between LEK S.A. and Sandoz.

2Supply Chain Resilience

The resilience of LEK S.A.'s Indian supply chain is closely tied to its exclusive partnership with Sandoz Private Limited. The lack of backup suppliers and limited formulation diversity may expose LEK S.A. to risks such as supply interruptions or regulatory changes affecting Sandoz. Additionally, reliance on a single supplier may limit LEK S.A.'s ability to adapt to market changes or diversify its product offerings.

3Strategic Implications

LEK S.A.'s sourcing pattern, characterized by exclusive reliance on Sandoz Private Limited, may impact its competitive position by limiting flexibility and responsiveness to market dynamics. For Indian exporters, this presents an opportunity to diversify LEK S.A.'s supplier base by offering alternative products or formulations that meet LEK S.A.'s quality standards and regulatory requirements. Establishing a relationship with LEK S.A. could lead to a more diversified and resilient supply chain for the company.

Importing Pharmaceuticals into Poland — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Poland

1Regulatory Authority & Framework

In Poland, the Chief Pharmaceutical Inspectorate (GIF) is the primary regulatory authority overseeing the import and distribution of medicinal products. Key legislation governing pharmaceutical imports includes the Pharmaceutical Law, which outlines requirements for marketing authorization, import licensing, and compliance with Good Manufacturing Practice (GMP). The marketing authorization pathway for Indian generics involves obtaining approval from the GIF, ensuring that imported products meet Polish and European Union standards for safety, efficacy, and quality. (cms.law)

2Import Licensing & GMP

Import licensing requirements in Poland stipulate that any activity involving the importation of medicinal products from outside the European Union or European Free Trade Association (EFTA) countries, which includes storage, quality control at batch release, and distribution, constitutes an import requiring GIF authorization. Compliance with GMP is mandatory for all pharmaceutical products, ensuring that manufacturing processes meet high-quality standards. Recognition of GMP certificates from the European Union, World Health Organization (WHO), and Pharmaceutical Inspection Co-operation Scheme (PIC/S) is accepted, facilitating the importation of generics from India. (cms.law)

Quality & Labeling

LEK S.a. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

LEK S.A. focuses on importing generic medicines and biosimilars, particularly in the central nervous system (CNS) and psychiatric therapeutic categories, with products like Citalopram and Escitalopram. This strategic focus aligns with market demand for affordable and effective treatments in these areas. The company's portfolio concentration on these products indicates a targeted approach to meet specific patient needs and market demands.

2Sourcing Profile

LEK S.A.'s sourcing strategy is centered on importing finished pharmaceutical formulations from Sandoz Private Limited, with a focus on generic drugs in the CNS and psychiatric categories. This approach leverages Sandoz's expertise and established product lines, ensuring a consistent supply of high-quality generics. India's role as a major supplier of generic medicines aligns with LEK S.A.'s procurement strategy, providing access to a diverse range of cost-effective products.

3Market Positioning

Based on its product mix, LEK S.A. serves the retail pharmacy segment in Poland, supplying generic CNS and psychiatric medications to pharmacies and healthcare providers. The company's focus on these therapeutic areas positions it to address the needs of patients requiring mental health treatments, contributing to the accessibility and affordability of such medications in the Polish market.

Seller's Guide — How to Become a Supplier to LEK S.a.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with LEK S.A. by offering alternative products or formulations that meet the company's quality standards and regulatory requirements. Gaps in LEK S.A.'s current sourcing include the potential for diversification in product offerings and the inclusion of additional therapeutic areas. Indian exporters can explore these opportunities by aligning their products with LEK S.A.'s strategic focus and market demands.

2Requirements & Qualifications

Indian exporters seeking to supply LEK S.A. must ensure that their products comply with Polish and European Union regulations, including obtaining marketing authorization from the Chief Pharmaceutical Inspectorate. Products must meet GMP standards, with certificates from recognized authorities such as the EU, WHO, or PIC/S. Additionally, compliance with Polish labeling requirements, batch testing, stability standards, and serialization mandates is essential.

3How to Approach

Frequently Asked Questions — LEK S.a.

What products does LEK S.a. import from India?

LEK S.a. imports 2 pharmaceutical products across 1 categories. Top imports: Citalopram ($5.6M), Escitalopram ($5.6M).

Who supplies pharmaceuticals to LEK S.a. from India?

LEK S.a. sources from 1 verified Indian suppliers. The primary supplier is Sandoz Private Limited (100.0% of imports, $2.1M).

What is LEK S.a.'s total pharmaceutical import value?

LEK S.a.'s total pharmaceutical import value from India is $11.3M, based on 286 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does LEK S.a. focus on?

LEK S.a. imports across 1 categories. The largest: CNS & Psychiatric (100.0%).

Get Full LEK S.a. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.